breast cancer

News

ASCO26: Celcuity punished as trial disappoints investors

Celcuity is still confident it has a winner with its breast cancer treatment, gedatolisib, but investors seem less convinced by new VIKTORIA-1 data.

News

ASCO26: After negative adcomm, AZ builds case for oral SERD

AstraZeneca showcases new data from the SERENA-6 data of camizestrant in breast cancer that it hopes will get FDA's review of the drug back on track.

News

FDA delays verdict on AZ breast cancer drug

After an advisory committee setback, AstraZeneca has a chance to make the case for its oral SERD camizestrant for breast cancer.

News

Datroway is first TROP2 drug for frontline breast cancer

AZ and Daiichi's Datroway has been cleared by the FDA as first-line treatment for triple-negative breast cancer patients ineligible for immunotherapy.

News

Pfizer, Arvinas join SERD club with Veppanu approval

Arvinas and Pfizer's Veppanu is the first PROTAC – and third oral SERD for breast cancer – to be approved by the FDA.

News

FDA's ODAC delivers one loss, one win for AstraZeneca

The FDA's cancer drugs committee backs AstraZeneca's Truqap in prostate cancer, but is unmoved by data for breast cancer candidate camizestrant.

ASCO26: Celcuity punished as trial disappoints investors

ASCO26: After negative adcomm, AZ builds case for oral SERD

FDA delays verdict on AZ breast cancer drug

Datroway is first TROP2 drug for frontline breast cancer

Pfizer, Arvinas join SERD club with Veppanu approval

FDA's ODAC delivers one loss, one win for AstraZeneca

Anthropic puts life sciences at heart of new AI model

Discover a new era of healthcare panel engagement: Grounded ...

breast cancer

Editor's Picks